Purpose / DescriptionEXPEDITION-8 was a single-arm, multicenter, international phase 3b trial to evaluate the efficacy of the fixed-dose combination of glecaprevir-pibrentasvir for 8 weeks in treatment-naïve participants with GT 1, 2, 3, 4, 5, or 6 chronic HCV and compensated cirrhosis. For the enrolled individuals 67% (231 of 343) had genotype 1 HCV. By intent-to-treat (ITT) analysis, the SVR12 response rates were 98% overall and greater than 95% with all HCV genotypes.